04:45 AM EDT, 07/13/2026 (MT Newswires) -- Poolbeg Pharma (POLB.L) dosed the first patient for its Polb 001 Topical clinical study to evaluate its lead asset, Polb 001, for the preventative treatment of Cytokine Release Syndrome. The trial will involve patients with relapsed/refractory multiple myeloma who are dosed with Johnson & Johnson's (JNJ.F) bispecific antibody teclistamab, according to a Monday release. The clinical-stage biopharmaceutical company expects to publish interim data from the study in the late summer of 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.